Humira biosimilars at discounted prices to meet market demand for accessible treatment
Several biosimilars to AbbVie’s monoclonal antibody therapeutic Humira were launched by various pharmaceutical giants this week in the US, with more expected to be released by the end of the year as the patent expires.
AbbVie’s top-selling therapeutic Humira for the treatment of arthritis has seen a market shift towards biosimilars of the monoclonal antibody (mAb) launched at discounted prices compared to Humira. From pharmaceutical giants such as Sandoz and Organon/Samsung Bioepis entering the mAb market in the last week, the availability of treatment options marks a significant milestone for accessible treatment options for millions of autoimmune disease patients.
The partnership between Organon and Samsung Bioepis launched the biosimilar Hadlima in the US, listed at an 85% discount rate of Humira at USD $1038 per month compared to Humira’s USD $6922 per month. Hadlima functions as a tumour necrosis factor (TNF) blocker for the indications of rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, and other inflammatory diseases. Other biosimilars released in the past week include Sandoz’s Hyrimoz, at a 5% discount to Humira’s price, and an unbranded version at an 81% discount. Boehringer Ingelheim also released Cyltezo at a 5–7% price drop. Amgen was the first company to release a biosimilar of Humira in the US earlier this year at a 5% and 55% discount, depending on the purchaser.
Though Organon and Samsung Bioepis did not confirm whether pharmacy benefit managers (PBMs), who negotiate insurance coverage for large employers and health insurance plans, had secured reimbursement of Hadlima, healthcare experts had previously stated their expectations that some biosimilars of Humira would debut with a discount in order to appeal to these PBMs.
Unlike generics, biosimilars are not necessarily exact copies of an innovative drug product whose patent has expired. While both are often touted as cheaper versions of name-brand drugs, biosimilars may achieve the same therapeutic and clinical result without exact duplication – they are drugs that are ‘highly similar’. Additionally, biosimilars aim to model the effects of drug products made from living organisms as therapeutic ingredients while generics are copies of synthetic drugs.
CEO of Organon Kevin Ali stated of the launch: “As the largest loss-of-exclusivity event in pharmaceutical history, this is a singular moment for the US healthcare system to embrace biosimilars. Every stakeholder should be invested in the success of this market to realise the value biosimilars can create for patients, providers, and the US healthcare economy. We are thrilled to now provide Hadlima in the US at a more affordable cost and expand much-needed access to adalimumab.”
At least nine drug products considered to be clinical copies of Humira are expected to be released in the US by the end of 2023, with companies such as Pfizer and Celltrion announcing plans for their own biosimilar launches.
Sources
1. Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount [Accessed July 3, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/organon-samsung-bioepis-launch-copycat-arthritis-drug-humira-85-discount-2023-07-01/
2. Sandoz launches rival version of AbbVie’s arthritis drug Humira [Accessed July 3, 2023] https://www.reuters.com/business/healthcare-pharmaceuticals/sandoz-launches-rival-version-abbvies-arthritis-drug-humira-2023-07-01/
3. Organon & Samsung Bioepis Announce US Launch of HUMIRA Biosimilar HADLIMATM (adalimumab-bwwd) in Multiple Presentations Consistent with Originator [Accessed July 3, 2023] https://www.organon.com/news/organon-samsung-bioepis-announce-us-launch-of-humira-biosimilar-hadlima-adalimumab-bwwd-in-multiple-presentations-consistent-with-originator/
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Pharmapack 2024 - From the Floor
Paris once again welcomes Europe’s leading trade show in pharmaceutical packaging and drug delivery innovation. Join our content team as Pharmapack 2024 opens its doors to leading experts and innovators in pharmaceutical packaging and drug delive... -
News On Track at Pharmapack 2024 - The Track Sponsor interview: BD Pharmaceuticals
January 2024 brings both a new year and Europe’s leading packaging and drug delivery event. Bringing the world’s experts in pharmaceutical packaging together in Paris, France, Pharmapack 2024 brings exciting opportunities to learn and colla... -
News CPHI Pharma Awards 2023 – API Development and Innovation Winners: Snapdragon Chemistry, a Cambrex Company
After another year of impressive nominations for the CPHI Pharma Awards our winners were announced at CPHI Barcelona in October. In this series of interviews, we speak to the teams behind the award-winning projects, concepts, and technologies. -
News PharmaKure gains authorisation for next stage testing on Alzheimer's treatment
Clinical stage pharmaceutical company PharmaKure gains permission from UK authorities to enter into further testing for PK051 for the treatment of patients with mild cognitive impairment associated with Alzheimer's disease. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News Navigating the Future: Challenges and Opportunities in Pharma Innovation and Investment – CPHI Barcelona 2023 Roundtable Report
In this comprehensive downloadable report, hear from a range of experts in finance and investment in the pharma industry on what investment trends will be shaping the future of the industry, in Catalonia, and the wider world. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance